Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None2021202020192018201720162015 Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks 02/13/2019 Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions 01/04/2019 Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting 12/03/2018 Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting 11/29/2018 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 11/05/2018 Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs 10/09/2018 Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma 09/05/2018 Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018 08/29/2018 Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies 08/07/2018 Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer 07/20/2018 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 31 - 40 of 70
Year None2021202020192018201720162015 Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks 02/13/2019 Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions 01/04/2019 Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting 12/03/2018 Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting 11/29/2018 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 11/05/2018 Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs 10/09/2018 Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma 09/05/2018 Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018 08/29/2018 Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies 08/07/2018 Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer 07/20/2018 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 31 - 40 of 70
Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks 02/13/2019
Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions 01/04/2019
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting 12/03/2018
Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting 11/29/2018
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 11/05/2018
Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma 09/05/2018
Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018 08/29/2018
Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies 08/07/2018
Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer 07/20/2018